Search - tctmd.com

Displaying 41 - 53 of 53

Sort: Relevancy | Date

News Conference News AHA 2015

Is Watchman Cost-effective? That Depends Where You Look

Todd Neale

November 07, 2015

News Industry News

ACC prepares to launch two afib-related registry programs

August 14, 2015

News Daily News

Statement on LAA Closure Highlights Key Issues for Growing Field

July 02, 2015

News Industry News

Boston Scientific Announces Scheduled Presentations at Heart Rhythm Society 2015

May 11, 2015

News Daily News

Study Documents Complications of LAA Closure With the Lariat Device

May 05, 2015

News Conference News TCT 2014

LAA Closure Edges Out Medical Therapy for Cost-effectiveness in AF

September 14, 2014

News Daily News

LAA Occlusion More Cost-effective Than Both Warfarin and Dabigatran for A-fib Patients

Yael L. Maxwell

June 07, 2013

News Daily News

ASAP Published: Watchman a Safe Option for A-fib Patients Ineligible for Warfarin

Yael L. Maxwell

April 12, 2013

News Daily News

ASAP Publicado: Watchman es una Opción Segura para Pacientes con FA No Aptos para tomar Warfarina

Yael L. Maxwell

April 12, 2013

News Daily News

PROTECT AF: Watchman Device Improves Quality of Life in A-fib Patients

Jason Kahn

February 28, 2013

News Daily News

PROTECT AF: El Dispositivo Watchman Mejora la Calidad de Vida de Pacientes con Fibrilación Auricular

Jason Kahn

February 28, 2013

Presentation

Quality-of-Life Assessment in the Randomized PROTECT AF Trial of Patients at Risk for Stroke with Nonvalvular A-fib

Presenter: 147572|Oluseun Alli

February 27, 2013

Presentation TCT 2012

Quality-of-Life and Cost-Effectiveness After LAA Closure

Presenter: Vivek Reddy

October 23, 2012

Advertisement

Is Watchman Cost-effective? That Depends Where You Look

ACC prepares to launch two afib-related registry programs

Statement on LAA Closure Highlights Key Issues for Growing Field

Boston Scientific Announces Scheduled Presentations at Heart Rhythm Society 2015

Study Documents Complications of LAA Closure With the Lariat Device

LAA Closure Edges Out Medical Therapy for Cost-effectiveness in AF

LAA Occlusion More Cost-effective Than Both Warfarin and Dabigatran for A-fib Patients

ASAP Published: Watchman a Safe Option for A-fib Patients Ineligible for Warfarin

ASAP Publicado: Watchman es una Opción Segura para Pacientes con FA No Aptos para tomar Warfarina

PROTECT AF: Watchman Device Improves Quality of Life in A-fib Patients

PROTECT AF: El Dispositivo Watchman Mejora la Calidad de Vida de Pacientes con Fibrilación Auricular

Quality-of-Life Assessment in the Randomized PROTECT AF Trial of Patients at Risk for Stroke with Nonvalvular A-fib

Quality-of-Life and Cost-Effectiveness After LAA Closure

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content